Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone)

The FSH component binds to FSH receptors on granulosa cells, promoting follicular growth and estradiol production. The LH component binds to LH receptors on theca and luteal cells, supporting the final maturation of the dominant follicle and triggering ovulation. Together they mimic the natural hormonal surge required for successful egg release.

The dose of Meriofert is individualized by the prescribing clinician based on the patient’s age, weight, underlying diagnosis, and response to prior stimulation. Dosage regimens are adjusted using serial ultrasound and hormone monitoring, and the prescriber sets the exact amount and schedule for each treatment cycle.

Meriofert is not intended for use in women who are already pregnant, and it should be discontinued once pregnancy is confirmed. Safety data for breastfeeding are limited, and the drug is generally avoided during lactation unless the benefits clearly outweigh potential risks, as determined by a qualified healthcare professional.

To place an order, submit an enquiry on the Meriofert product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Meriofert combines both FSH and LH in a single formulation, which can simplify treatment protocols compared with using separate FSH‑only and LH‑only preparations. This dual‑action approach may reduce the number of injections and improve patient compliance, while delivering comparable efficacy to other recombinant gonadotropin products when used under specialist supervision.

Meriofert must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If the product must be transported, use validated cold‑chain containers to maintain the required temperature range throughout delivery.

Meriofert is administered by subcutaneous injection, typically into the abdominal wall or thigh. The injection is performed using a sterile needle and syringe, following aseptic technique. The exact injection site, volume, and timing are determined by the treating physician based on the individual stimulation protocol.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, abdominal pain, and fluid accumulation; allergic reactions ranging from rash to anaphylaxis; thromboembolic events; and the possibility of multiple pregnancy. Patients should be monitored closely for early signs of these complications.

Meriofert is contraindicated in women with known hypersensitivity to any component of the product, active ovarian cysts, uncontrolled thyroid disease, or those who are already pregnant. It should also be used with caution in patients with severe renal or hepatic impairment, and it is not recommended for individuals with a history of thromboembolic disorders unless specifically advised by a specialist.